TABLE 1.
Characteristics of patients exposed to eltrombopag
| Characteristics | Total (n = 156) | ITP duration at eltrombopag initiation | |
|---|---|---|---|
| <6 months (n = 95) | ≥6 months (n = 61) | ||
| Age at ITP diagnosis, mean (±SD), years | 60.2 (±20.9) | 60.5 (±21.4) | 59.7 (20.4) |
| Women, n (%) | 77 (49.4%) | 45 (47.4%) | 34 (55.7%) |
| Cardiovascular risk factors a , n (%) | 89 (57.1%) | 56 (58.9%) | 33 (54.1%) |
| History of venous thrombosis, n (%) | 9 (5.8%) | 6 (6.3%) | 3 (4.9%) |
| Charlson's Comorbidity Index score b | |||
| 0, n (%) | 94 (61.0%) | 50 (53.8%) | 44 (72.1%) |
| 1–2, n (%) | 41 (26.6%) | 28 (30.1%) | 13 (21.3%) |
| ≥3, n (%) | 19 (12.3%) | 15 (16.1%) | 4 (6.6%) |
| Median platelet count at ITP diagnosis (Q1–Q3), ×109/L | 8.0 (5.0–33.0) | 7.0 (5.0–17.0) | 20.0 (5.0–38.0) |
| Bleeding at ITP diagnosis, n (%) | 118 (75.6%) | 76 (80.0%) | 42 (68.9%) |
| Median time from ITP diagnosis to eltrombopag initiation (range), months | 3.3 (0.1–82.2) | 1.6 (0.1–5.9) | 12.5 (6.0–82.2) |
| Median platelet count at eltrombopag initiation (Q1–Q3), ×109/L | 26.0 (12.0–41.0) | 24.0 (11.0–41.0) | 29.0 (15.0–41.0) |
| Bleeding before eltrombopag initiation, n (%) | 132 (84.6%) | 80 (84.2%) | 52 (85.2%) |
| Lines of ITP treatments before eltrombopag initiation, median (range) | 2 (0–5) | 2 (0–4) | 2 (0–5) |
| Eltrombopag in ITP treatment history | |||
| 1st line, n (%) | 4 (2.6%) | 3 (3.2%) | 1 (1.6%) |
| 2nd line, n (%) | 52 (33.3%) | 41 (43.2%) | 11 (18.0%) |
| 3rd line, n (%) | 56 (35.9%) | 32 (33.7%) | 24 (39.3%) |
| 4th line, n (%) | 26 (16.7%) | 14 (14.7%) | 12 (19.7%) |
| >4th line, n (%) | 18 (11.5%) | 5 (5.3%) | 13 (21.3%) |
| Previous treatments before eltrombopag initiation | |||
| Corticosteroids, n (%) | 150 (96.2%) | 91 (95.8%) | 59 (96.7%) |
| Intravenous immunoglobulin, n (%) | 106 (67.9%) | 66 (69.5%) | 40 (65.6%) |
| Dapsone, n (%) | 28 (17.9%) | 11 (11.6%) | 17 (27.9%) |
| Danazol, n (%) | 8 (5.1%) | 2 (2.1%) | 6 (9.8%) |
| Rituximab, n (%) | 26 (16.7%) | 5 (5.3%) | 21 (34.4%) |
| Romiplostim, n (%) | 12 (7.7%) | 5 (5.3%) | 7 (11.5%) |
| Azathioprine, n (%) | 2 (1.3%) | 0 | 2 (3.3%) |
| Mycophenolate, n (%) | 0 | 0 | 0 |
| Ciclosporin, n (%) | 1 (0.6%) | 1 (1.1%) | 0 |
| Hydroxychloroquine, n (%) | 14 (9.0%) | 6 (6.3%) | 8 (13.1%) |
| Vinblastine, n (%) | 5 (3.2%) | 5 (5.3%) | 0 |
| Splenectomy, n (%) | 0 | 0 | 0 |
| Concomitant ITP treatment at eltrombopag initiation | |||
| Corticosteroids | 76 (48.7%) | 52 (54.7%) | 24 (39.3%) |
| Intravenous immunoglobulin (IgIV) c | 76 (48.7%) | 57 (60.0%) | 19 (31.1%) |
| Dapsone | 5 (3.2%) | 3 (3.2%) | 2 (3.3%) |
| Danazol | 3 (1.9%) | 2 (2.1%) | 1 (1.6%) |
| Hydroxychloroquine | 8 (5.1%) | 5 (5.3%) | 3 (4.9%) |
| Immunosuppressors | 2 (1.3%) | 1 (1.0%) | 1 (1.6%) |
| Romiplostim | 5 (3.2%) | 1 (1.0%) | 4 (6.6%) |
| Rituximab c | 20 (12.8%) | 5 (5.3%) | 15 (24.6%) |
Abbreviation: ITP, immune thrombocytopenia.
a
Excluding age (>50 years for men and >60 years for women) and sex.
b
Missing data for 2 patients.
c
Patients were considered as concomitantly exposed to intravenous immunoglobulin in case of infusion during the previous month, and to rituximab in case of infusion during the previous 6 months.